TrialPloS one2023

Subcutaneous ketamine infusion in palliative patients for major depressive disorder (SKIPMDD)-Phase II single-arm open-label feasibility study.

Wei Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.